Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri

Neurology

Volumn 70, Issue 8, 2008, Pages 590-595

  Kaloshi, G ^a   Everhard, S ^b   Laigle Donadey, F ^a   Marie, Y ^b   Navarro, S ^a   Mokhtari, K ^a   Idbaih, A ^a,b   Ducray, F ^a,b   Thillet, J ^b   Hoang Xuan, K ^a,b,c   Delattre, J Y ^a,b,c   Sanson, M ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GENETIC MARKER; GLIOMA; GLIOMATOSIS CEREBRI; GLIOSIS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 39749102303     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000299896.65604.ae     Document Type: Article

References (22)

1. Sanson M, Cartalat-Carel S, Taillibert S, et al. Initial chemotherapy in gliomatosis cerebri. Neurology 2004;63:270-275.
2. Levin N, Gomori JM, Siegal T.Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. Neurology2004;63:354-356.
3. Ware ML, Hirose Y, Scheithauer BW, et al. Genetic aberrations in gliomatosis cerebri. Neurosurgery. 2007;60:150-158.
4. Taillibert S, Chodkiewicz C, Laigle-Donadey F, Napolitano M, Cartalat-Carel S, Sanson M. Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol 2006;76:201-205.
5. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-2722.
6. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479.
7. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-3138.
8. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10; p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-9861.
9. Idbaih A, Marie Y, Pierron G, et al. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 2005;58:483-487.
10. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
11. Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006;60:740-743.
12. Braeuninger S, Schneider-Stock R, Kirches E, et al. Evaluation of molecular genetic alterations associated with tumor progression in a case of gliomatosis cerebri. J Neurooncol 2007;82:23-27.
13. Hecht BK, Turc-Carel C, Chatel M, et al. Chromosomes in gliomatosis cerebri. Genes Chromosomes Cancer 1995;14:149-153.
14. Mawrin C. Molecular genetic alterations in gliomatosis cerebri: what can we learn about the origin and course of the disease? Acta Neuropathol (Berl) 2005;110:527-536.
15. Mawrin C, Kirches E, Schneider-Stock R, et al. Alterations of cell cycle regulators in gliomatosis cerebri. J Neurooncol 2005;72:115-122.
16. Mawrin C, Lins H, Kirches E, et al. Distribution of p53 alterations in a case of gliomatosis cerebri. Hum Pathol 2003;34:102-106.
17. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-2714.
18. Jenkinson MD, du Plessis DG, Smith TS, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884-1891.
19. Zlatescu MC, Tehrani Yazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001;61:6713-6715.
20. Dong SM, Pang JC, Poon WS, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 2001;60:808-816.
21. Mollemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-385.
22. Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006;24:4746-4753.